A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleotide/Nucleoside Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

Trial Profile

A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleotide/Nucleoside Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Lersivirine (Primary) ; Darunavir; Etravirine; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Pfizer; ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 May 2016 This trial was completed in Italy according to the European Clinical Trials Database.
    • 20 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top